[ANNOUNCEMENT] HTA COUNCIL RELEASES ITS PRELIMINARY RECOMMENDATION ON THE FINANCING OF DOACS FOR NONVALVULAR ATRIAL FIBRILLATION
[ANNOUNCEMENT] HTA COUNCIL RELEASES ITS PRELIMINARY RECOMMENDATION ON THE NON-FINANCING OF CEREBROLYSIN FOR POST ISCHEMIC STROKE
HTAC GUIDANCE: PNF INCLUSION OF RECOMBINANT HUMAN ERYTHROPOIETIN (EPOETIN ALFA) 4000 IU/ML SOLUTION FOR INJECTION (IV/SC) 1ML PRE-FILLED SYRINGE
HTAC GUIDANCE: PNF INCLUSION OF FILGRASTIM 300 MCG/0.9 ML SOLUTION (IV, SC), 0.9 ML PRE-FILLED SYRINGE
[ANNOUNCEMENT] CEREMONIAL TURNOVER OF HTA IMPLEMENTATION FROM THE DEPARTMENT OF HEALTH TO THE DEPARTMENT OF SCIENCE AND TECHNOLOGY
[ANNOUNCEMENT] HTA COUNCIL RELEASES ITS PRELIMINARY RECOMMENDATION ON THE FINANCING OF DAPAGLIFLOZIN FOR PATIENTS WITH TYPE 2 DIABETES MELLITUS
[Department Circular No. 2023-0059] HEALTH TECHNOLOGY ASSESSMENT COUNCIL (HTAC) RECOMMENDATION FOR THE INCLUSION OF DEFERASIROX 90 MG AND 180 MG FILM-COATED TABLET (FCT) FOR CHRONIC IRON OVERLOAD DUE TO REPETITIVE BLOOD TRANSFUSIONS IN PATIENTS 2 YEARS OLD AND ABOVE IN THE PHILIPPINE NATIONAL FORMULARY (PNF)
[Department Circular No. 2023-0061] HEALTH TECHNOLOGY ASSESSMENT COUNCIL (HTAC) RECOMMENDATION FOR THE INCLUSION OF FILGRASTIM 300 MCG/0.9 ML SOLUTION (IV, SC), 0.9 ML PRE-FILLED SYRINGE FOR THE TREATMENT OF NEUTROPENIA IN PATIENTS UNDERGOING BONE MARROW TRANSPLANTATION AND PATIENTS RECEIVING MYELOSUPPRESSIVE CANCER CHEMOTHERAPY IN THE PHILIPPINE NATIONAL FORMULARY (PNF)
